Pesticide disrupts neuronal potentiation
The pesticide deltamethrin is widely considered a safer alternative to other chemicals, such as organophosphates due to being less toxic to mammals. However, previous studies in mice showed that deltamethrin exposure at early stages of development can lead to neuronal toxicity, but scientists do not understand the mechanism involved. Therefore, Leandra Koff and a team led by Fernanda Laezza from the Sealy Center of Environmental Health & Medicine at the University of Texas Medical Branch and colleagues in the U.S. investigated how deltamethrin induces neuronal toxicity and published their in Molecular & Cellular Proteomics.

The team focused on brain-derived extracellular vesicles, or BDEVs, structures that transport molecules, such as signaling proteins, between cells in the brain. Because changes in the BDEV proteome can be a sign of disease, the team used a mass spectrometry–based approach to compare the protein content of BDEVs in mice exposed to deltamethrin and controls. They found several differentially expressed proteins between the two groups. Some alterations are associated with neuronal structure, transport and long-term potentiation, which promotes synaptic connections and plays a role in learning and memory. These proteomic differences could be one explanation for neuronal toxicity due to impaired nutrient transport and growth.
BDEV protein levels could be used as biomarkers to evaluate the risk of neurodevelopmental disorders. More research is needed to understand how these proteins disrupt neuronal function at later stages of development.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Teaching AI to listen
A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.